About Us


Revive Therapeutics Ltd. is a publicly-traded company listed on the OTCQB: RVVTF in the U.S. and the TSX Venture: RVV in Canada.

 

Revive's lead product is in the treatment for acute gout flares, which completed a Phase 2a study in the U.S.

 

Also, Revive is advancing developments in rare diseases such as, Cystinuria, which was granted FDA Orphan Drug Status, Wilson's disease and Rett syndrome (partnered with Rettsyndrome.org).

Read more

news

News

August 18, 2016

Revive Completes $1,500,000 Non-Brokered Private Placement

Read more
July 06, 2016

Revive Therapeutics Ltd. Announces US FDA Acceptance of IND of Bucillamine for the Treatment of Cystinuria

Read more
July 05, 2016

Revive Therapeutics Announces New CEO and New President

Read more
June 20, 2016

Revive Announces Completion of Rights Offering for Gross Proceeds of $844,693 to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria

Read more
May 30, 2016

Announces $1,500,000 Best-Efforts Non-Brokered Private Placement

Read more
Newsletter
Corporate presentation